Rigel Pharmaceuticals, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Vignette Gets Rights To BCMA×CD3 Bispec

Aiming to become profitable in 2025, HUTCHMED (China) Limited is likely to move away from running costly late-stage international clinical trials by itself, primarily in the US, and is instead seeki

HUTCHMED (China) Limited looks set to step up its first major effort to gain a foothold in the US autoimmune space after positive results from the China-only Phase III ESLIM-01 clinical study with so

Fewer investment dollars are going to oncology-focused and platform technology companies, but there has been an uptick in investment in disease areas – even at the preclinical stage – that just a few